1-Hexanol, 2-ethyl-
RTECS #
MP0350000
CAS #
Updated
December 2018
Molecular Weight
130.26
Molecular Formula
C8H18O
Synonyms
2-Aethylhexanol (German)
2-Ethyl-1-hexanol
2-Ethylhexanol
2-Ethylhexyl alcohol
Ethylhexanol
2-Ethyl-1-hexanol
2-Ethylhexanol
2-Ethylhexyl alcohol
Ethylhexanol
Skin and Eye Irritation and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
eye /rabbit | 20 mg | severe | AJOPAA 29,1363,1946 |
eye /rabbit | 20 mg/24H | moderate | 85JCAE -,200,1986 |
eye /rabbit | 20 µg | moderate | HPV106 -,-,2002 |
skin /rabbit | 0.5 mL | severe | HPV106 -,-,2002 |
skin /rabbit | 415 mg open irritation test | mild | UCDS** 11/11/1969 |
skin /rabbit | 500 mg/24H | moderate | FCTXAV 17,775,1979 |
Mutation Data and Reference
System Test | Route/Organism/Tissue | Dose | Reference |
---|---|---|---|
mutation in microorganisms | /Salmonella typhimurium | 500 µmol/L (+enzymatic activation step) | EVHPAZ 45,111,1982 |
Reproductive Effects Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
oral/rat | 1628 mg/kg (12D pregnant) | Reproductive: Specific developmental abnormalities: Musculoskeletal system Reproductive: Specific developmental abnormalities: Urogenital system | TJADAB 35,41,1987 |
oral/mouse | 12 gm/kg (7-14D pregnant) | Reproductive: Effects on newborn: Live birth index (Litter size (e.g., # fetuses per litter; measured after birth) Reproductive: Effects on newborn: Viability index (e.g., # alive at day 4 per # born alive) Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) | NTIS** PB85-220143 |
oral/mouse | 12200 mg/kg (6-13D pregnant) | Reproductive: Effects on fertility: Litter size (e.g., # fetuses per litter; measured before birth) Reproductive: Effects on newborn: Live birth index (Litter size (e.g., # fetuses per litter; measured after birth) Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) | TCMUD8 7,29,1987 |
oral/rat | 6500 mg/kg (6-15D pregnant) | Reproductive: Other effects on female Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | HPV106 -,-,2002 |
oral/rat | 13000 mg/kg (6-15D pregnant) | Reproductive: Other effects on female Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Specific developmental abnormalities: Musculoskeletal system | HPV106 -,-,2002 |
oral/mouse | 12200 mg/kg (7-14D pregnant) | Reproductive: Other effects on female Reproductive: Effects on newborn: Live birth index (Litter size (e.g., # fetuses per litter; measured after birth) Reproductive: Effects on newborn: Viability index (e.g., # alive at day 4 per # born alive) | HPV106 -,-,2002 |
Tumorigenic Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
oral/mouse | lowest published toxic dose: 270000 mg/kg/72W- intermittent | Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Liver: Tumors Tumorigenic: Increased incidence of tumors in susceptible strains | HPV341 -,-,2001 |
Acute Toxicity Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
In Vitro/Human, neuroblastoma | Inhibitor Concentration (50 percent kill): 15.1 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TOXRE* 2,729,2015 |
In Vitro/Human, skin | Inhibitor Concentration Low: 60 µL/well/60M | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,1476,2013 |
In Vitro/Rabbit, ocular | Inhibitor Concentration Low: 5 pph/5M | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 25,1425,2011 |
In Vitro/Rat, neurons | Inhibitor Concentration Low: 0.5 mmol/L/24H | In Vitro Toxicity Studies: Cell membrane integrity (prelabeled cells): release of radioactive isotopes ([51Cr], [3H]-thymidine, [3H]-proline, [35S]- or [75Se]-methionine, 5-[125I]-2-deoxy-uridine) or fluorescent dyes (bis-carboxyethyl-carboxyfluorescein (BCECF) or calcein-AM) | TOXRE* 2,729,2015 |
inhalation/guinea pig | lowest published toxic concentration: 227 ppm/6H | Behavioral: Somnolence (general depressed activity) Lung, Thorax, or Respiration: Dyspnea | HPV106 -,-,2002 |
inhalation/man | lowest published toxic concentration: 10 ppm/4H | Olfaction: Other olfaction effects Eye: Conjunctiva irritation Behavioral: Excitement | NRTXDN 28,347,2007 |
inhalation/mouse | lowest published toxic concentration: 227 ppm/6H | Behavioral: Somnolence (general depressed activity) Lung, Thorax, or Respiration: Dyspnea | HPV106 -,-,2002 |
inhalation/mouse | lowest published toxic concentration: 270 mg/m3 | Behavioral: Ataxia Lung, Thorax, or Respiration: Respiratory depression Liver: Other changes | VCVGK* -,115,1984 |
inhalation/mouse | lowest published toxic concentration: 44 ppm | Lung, Thorax, or Respiration: Respiratory depression | HPV106 -,-,2002 |
inhalation/rat | lowest published toxic concentration: 210 mg/m3 | Behavioral: Ataxia Lung, Thorax, or Respiration: Respiratory depression Liver: Other changes | VCVGK* -,115,1984 |
inhalation/rat | Lethal concentration: >2000 ppm/6H | KODAK* 21MAY1971 | |
inhalation/rat | lowest published toxic concentration: 227 ppm/6H | Behavioral: Somnolence (general depressed activity) Lung, Thorax, or Respiration: Dyspnea | HPV106 -,-,2002 |
inhalation/rat | lowest published toxic concentration: 0.85 mg/m3/4H | FEREAC 70,51623,2005 | |
intraperitoneal/mouse | lethal dose (50 percent kill): 726 mg/kg | HPV106 -,-,2002 | |
intraperitoneal/rat | lethal dose (50 percent kill): 650 mg/kg | Behavioral: Somnolence (general depressed activity) Lung, Thorax, or Respiration: Respiratory depression | HPV106 -,-,2002 |
intraperitoneal/rat | lethal dose (50 percent kill): 500 mg/kg | HYDRDA 3,201,1978 | |
oral/guinea pig | lethal dose (50 percent kill): 1860 mg/kg | ZHYGAM 20,575,1974 | |
oral/guinea pig | lethal dose (50 percent kill): 600 mg/kg | Liver: Other changes Kidney, Ureter, and Bladder: Other changes Blood: Changes in spleen | HPV106 -,-,2002 |
oral/human | lowest published lethal dose: 428.6 mg/kg | VCVGK* -,116,1984 | |
oral/mouse | lethal dose (50 percent kill): 2500 mg/kg | HPV106 -,-,2002 | |
oral/rabbit | lethal dose (50 percent kill): 1180 mg/kg | HPV106 -,-,2002 | |
oral/rat | lowest published lethal dose: 1516 mg/kg | HPV106 -,-,2002 | |
oral/rat | lethal dose (50 percent kill): 3730 mg/kg | HPV106 -,-,2002 | |
oral/rat | lethal dose (50 percent kill): 3730 mg/kg | Brain and Coverings: Recordings from specific areas of CNS Behavioral: Somnolence (general depressed activity) Lung, Thorax, or Respiration: Dyspnea | AIHAAP 34,493,1973 |
parenteral/mouse | lethal dose (50 percent kill): 1670 mg/kg | FCTXAV 17,775,1979 | |
parenteral/rat | lethal dose (50 percent kill): 4600 mg/kg | FCTXAV 17,775,1979 | |
skin/rabbit | lethal dose (50 percent kill): 1970 mg/kg | NPIRI* 1,61,1974 | |
skin/rat | lethal dose (50 percent kill): >3000 mg/kg | HPV106 -,-,2002 | |
subcutaneous/rat | lowest published lethal dose: 5.54 gm/kg | HPV106 -,-,2002 | |
subcutaneous/rat | lethal dose (50 percent kill): 650 mg/kg | NPIRI* 1,61,1974 |
Other Multiple Dose Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
inhalation/mouse | lowest published toxic concentration: 250 gm/m3/5D- intermittent | Immunological Including Allergic: Decreased immune response Immunological Including Allergic: Hypersensitivity delayed (multiple organ involvement) | TXAPA9 197,280,2004 |
inhalation/rat | lowest published toxic concentration: 102 mg/m3/4H/137D- intermittent | Behavioral: Irritability Lung, Thorax, or Respiration: Other changes | VCVGK* -,116,1994 |
inhalation/rat | lowest published toxic concentration: 1.5 mg/m3/90D- continuous | Liver: Other changes Kidney, Ureter, and Bladder: Other changes Nutritional and Gross Metabolic: Weight loss or decreased weight gain | VCVGK* -,116,1994 |
oral/mouse | lowest published toxic dose: 3247 mg/kg/17D- continuous | Behavioral: Food intake (animal) | NTIS** #PB91-185900 |
oral/mouse | lowest published toxic dose: 22500 mg/kg/90D- intermittent | Gastrointestinal: Other changes | FEREAC 70,51623,2005 |
oral/mouse | lowest published toxic dose: 9 gm/kg/11D- intermittent | Gastrointestinal: Other changes Liver: Changes in liver weight | FAATDF 29,31,1996 |
oral/mouse | lowest published toxic dose: 16250 mg/kg/13W- intermittent | Liver: Other changes Liver: Changes in liver weight | FAATDF 29,31,1996 |
oral/mouse | lowest published toxic dose: 29150 mg/kg/11D- intermittent | Endocrine: Differential effect of sex or castration on observed toxicity Nutritional and Gross Metabolic: Weight loss or decreased weight gain | HPV106 -,-,2002 |
oral/rat | lowest published toxic dose: 16250 mg/kg/13W- intermittent | Liver: Changes in liver weight Kidney, Ureter, and Bladder: Changes in kidney weight Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Transaminases | HPV098 -,-,2004 |
oral/rat | lowest published toxic dose: 24.5 gm/kg/14D- intermittent | Liver: Other changes Biochemical: Metabolism (intermediary): Lipids including transport | ATSUDG 12,274,1988 |
oral/rat | lowest published toxic dose: 2100 mg/kg/3W- continuous | Liver: Other changes | VCVGK* -,116,1994 |
oral/rat | lowest published toxic dose: 24000 mg/kg/60D- continuous | Brain and Coverings: Other degenerative changes Kidney, Ureter, and Bladder: Other changes Nutritional and Gross Metabolic: Weight loss or decreased weight gain | VCVGK* -,116,1994 |
oral/rat | lowest published toxic dose: 2970 mg/kg/9D- intermittent | Behavioral: Change in motor activity (specific assay) Behavioral: Ataxia Behavioral: Muscle contraction or spasticity | NTIS** OTS0540989 |
oral/rat | lowest published toxic dose: 9 gm/kg/11D- intermittent | Gastrointestinal: Ulceration or bleeding from stomach Liver: Changes in liver weight Kidney, Ureter, and Bladder: Changes in bladder weight | FAATDF 29,31,1996 |
oral/rat | lowest published toxic dose: 16250 mg/kg/13W- intermittent | Gastrointestinal: Other changes Liver: Changes in liver weight Kidney, Ureter, and Bladder: Changes in bladder weight | FAATDF 29,31,1996 |
oral/rat | lowest published toxic dose: 14 gm/kg/17D- intermittent | Liver: Changes in liver weight Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Phosphatases Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other hydrolases | BCSTB5 2,322,1974 |
oral/rat | lowest published toxic dose: 25200 mg/kg/3W- continuous | Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) | TOLED5 10,379,1982 |
oral/rat | lowest published toxic dose: 260 gm/kg/2Y- intermittent | Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | TOXID9 13,70,1993 |
oral/rat | lowest published toxic dose: 16250 mg/kg/13W- intermittent | Liver: Changes in liver weight Kidney, Ureter, and Bladder: Changes in kidney weight | HPV046 -,-,2004 |
oral/rat | lowest published toxic dose: 32500 mg/kg/13W- intermittent | Liver: Changes in liver weight Kidney, Ureter, and Bladder: Changes in kidney weight Nutritional and Gross Metabolic: Weight loss or decreased weight gain | HPV046 -,-,2004 |
oral/rat | lowest published toxic dose: 5500 mg/kg/11D- intermittent | Gastrointestinal: Other changes Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical: Metabolism (intermediary): Lipids including transport | HPV106 -,-,2002 |
oral/rat | lowest published toxic dose: 10780 mg/kg/11D- intermittent | Liver: Changes in liver weight Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical: Metabolism (intermediary): Lipids including transport | HPV106 -,-,2002 |
oral/rat | lowest published toxic dose: 25380 mg/kg/90D- continuous | Liver: Other changes Kidney, Ureter, and Bladder: Other changes | FEREAC 70,51623,2005 |
oral/rat | lowest published toxic dose: 22500 mg/kg/90D- intermittent | Liver: Other changes Biochemical: Effect on specific coenzyme: CoA | FEREAC 70,51623,2005 |
skin/rat | lowest published toxic dose: 20 mL/kg/16D- intermittent | Cardiac: Cardiomyopathy including infarction Liver: Fatty liver degeneration Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) | HPV106 -,-,2002 |
skin/rat | lowest published toxic dose: 7506 mg/kg/11D- intermittent | Endocrine: Changes in spleen weight Blood: Changes in other cell count (unspecified) Skin: After systemic exposure: Dermatitis, other | NTIS** OTS0536344 |
Reviews
Organization | Standard | Reference |
---|---|---|
TOXICOLOGY REVIEW | MUREAV 539,77,2003 | |
TOXICOLOGY REVIEW | TOLED5 140-141,261,2003 | |
TOXICOLOGY REVIEW | REPTED 25,192,2008 | |
TOXICOLOGY REVIEW | REPTED 22,291,2006 | |
TOXICOLOGY REVIEW | FCTOD7 47,1287,2009 | |
TOXICOLOGY REVIEW | MUREAV 750,141,2012 | |
TOXICOLOGY REVIEW | TOLED5 199,203,2010 | |
TOXICOLOGY REVIEW | REPTED 58,252,2015 | |
TOXICOLOGY REVIEW | FCTOD7 97,S119,2016 | |
TOXICOLOGY REVIEW | FCTOD7 97,S147,2016 | |
TOXICOLOGY REVIEW | FCTOD7 97,S157,2016 |
Standards and Regulations
NIOSH Documentation and Surveillance
Status in Federal Agencies
Organization | Reference |
---|---|
EPA TSCA Section 8(b) CHEMICAL INVENTORY | |
EPA TSCA Section 8(d) unpublished health/safety studies | |
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001 |
Page last reviewed: November 16, 2018
Content
source: National Institute for Occupational Safety and Health